Food and Drug Administration (FDA) lists "ileus" as a potential side effect of Ozempic
Individual Variability Peptide responses vary greatly
But everyone with knowledge of the industry, including the compounders themselves, worry that a single batch of a poorly made drug could kill or maim people and destroy confidence in their business
Last Published 04.01.2026 Effective Date: 04.01.2026 This policy addresses the use of erythropoiesis-stimulating agents (ESAs), including Aranesp (darbepoetin alfa), Epogen (epoetin alfa), Mircera (methoxy polyethylene glycol-epoetin beta [MPG-epoetin beta]), Procrit (epoetin alfa), and Retacrit (epoetin alfa)
[DOI] [PMC free article] [PubMed] [Google Scholar] 7.Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H